Sign in
Taking people in United StatesPhase 1

Rimegepant or zavegepant for migraine treated in the emergency department

Tests rimegepant or zavegepant for acute migraine in adults visiting the emergency department.

Key facts

Who runs it
University of South Florida
Where
Tampa, United StatesSee the site
Trial code
Registry title
A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department
Status
Recruiting
Phase
Phase 1
People taking part
100 people, planned
Started
15 Sept 2026
Expected to end
Aug 2027
Type of study
Interventional, 2 groups
Treatments tested
  • Rimegepant
  • Zavegepant
Record updated
27 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who come to the Emergency Department with a migraine headache. They get rimegepant or zavegepant during one visit and are followed for 28 days.

Age
At least 18 years old.
Sex
All sexes can join.
Disease stage
An acute migraine attack, with or without aura, as judged by the care team or by ICHD-3 criteria. The attack can last more than 72 hours. The person must have been headache free for more than 48 hours before this attack.
Earlier treatment
No pain medicine or headache-stopping medicine within 60 minutes before the study drug. No nasal decongestant within 1 hour before. No earlier use of CGRP-targeting migraine medicines, ever.

Main reasons for not taking part

  • Current pregnancy or breastfeeding
  • Recent or uncontrolled heart disease, diabetes or high blood pressure
  • Stroke within 3 months, or any stroke at age 65 or older
  • Raynaud's phenomenon, serious blood vessel disease in the limbs, severe liver problems or kidney disease stage 4
  • Allergy to rimegepant, zavegepant or their inactive ingredients

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • • At least 18 years of age; Capacity to provide informed consent (without a Representative); Emergency Department presentation for a headache consistent with migraine, based either on the treating clinical team's judgement, or fulfillment of International Classification of Headache Disorders (ICHD-3) criteria for migraine without aura or with typical aura, or for probable migraine without aura or with typical aura. It is acceptable if current headache duration is >72 hours. Must have been headache free for >48 hours prior to current attack; Willing to participate in post-discharge telephone assessments; English and/or Spanish speaking patients

Who cannot take part

  • • Use of intranasal decongestants within 1 hour prior to study drug administration, due to the potential to decrease absorption of intranasal zavegepant; Use of analgesics or abortive headache medications within 60 minutes of study medication administration; Use of the following drug/food categories with potential for drug interactions within 7 days or 5 half-lives, whichever is longer: 1) CYP3A strong or moderate inducers, 2) CYP3A4 strong inhibitors, 3) P-glycoprotein (P-gp) inhibitors, 4) OATP1B3 transporter potent inhibitors/inducers, 5) NTCP transporter potent inhibitors/inducers; History of ischemic cardiovascular disease, diabetes, or hypertension (diagnosed or likely based on multiple readings), that was recently diagnosed within 3 months of screening or is currently uncontrolled or unstable; History of any stroke within 3 months, or any lifetime stroke and age ≥65 years; History of significant peripheral vascular disease, as assessed by the investigator or qualified delegate; History of Raynaud's Phenomenon (medically diagnosed, or non-medically diagnosed with affirmative responses to both unusual sensitivity and finger color change with cold exposure); History of severe hepatic impairment, as assessed by the investigator or qualified delegate; History of kidney disease stage 4 (eGFR <30 mL/min/1.73 m2); History of hypersensitivity reaction to rimegepant, zavegepant, or to any included inactive ingredients; Lifetime use of CGRP-targeting acute or preventive migraine medications; In custody of law enforcement; Current pregnancy or lactation; All individuals of childbearing potential must have a negative pregnancy test at screening (urine or serum); A person is considered to be of childbearing potential if possessing female reproductive organs at birth, post-menarchal, has not reached a post-menopausal state (≥12 continuous months of amenorrhea with no cause identified other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis)

Where in United States

  • Tampa General Hospital Emergency RoomTampa, United StatesContact: Hope Brunner, RN, BSNTaking people

About the trial

What the trial wants to find out

Prospective, single-site, open-label, non-controlled pilot study consisting of two parallel trials. Participants will receive rimegepant or zavegepant for acute migraine treatment during a single Emergency Department visit, with post-discharge follow-up through 28 days. Participants will be allocated to either the rimegepant trial or the zavegepant trial. The study design does not include a placebo or active comparator control group, and the two gepant study drugs are not designed to function as active comparator groups. The objective in this investigation is to examine relief from either rimegepant or zavegepant in separate parallel trials.

The 2 groups in the trial

  • Rimegepant (Parallel Trial)Treatment being tested

    Participants receive a single oral dose of rimegepant 75 mg orally disintegrating tablet during an Emergency Department visit for the acute treatment of migraine. This arm represents one of two independent, parallel pilot trials evaluating the effectiveness and safety of gepant medications in the Emergency Department. This arm is not intended for comparison with the zavegepant arm.

    Treatment: Rimegepant

  • Zavegepant (Parallel Trial)Treatment being tested

    Participants receive a single dose of zavegepant 10 mg administered as an intranasal spray during an Emergency Department visit for the acute treatment of migraine. This arm represents one of two independent, parallel pilot trials evaluating the effectiveness and safety of gepant medications in the Emergency Department. This arm is not intended for comparison with the rimegepant arm.

    Treatment: Zavegepant

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Open-Label Study Evaluating the Effectiveness of Rimegepant ODT or Zavegepant Nasal Spray for Acute Treatment of Migraine in the Emergency Department
Plain-language title
Rimegepant or zavegepant for migraine treated in the emergency departmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
27 October 2026